Healthy
Conditions
Keywords
CPAP pressure of -5cm/water during cold, dry air exposure, CPAP pressure of 0cm/water during cold, dry air exposure, CPAP pressure of 5cm/water during cold, dry air exposure, CPAP pressure of 10cm/water during cold, dry air exposure
Brief summary
We hypothesize that continuous positive pressure applied to the airway will decrease the ability of the nose to warm and humidify inspired air compared to zero or negative pressure. We will use continuous positive airway pressure (CPAP), a device commonly used to treat patients with sleep apnea, to vary the pressure in the airway and determine if increased pressure decreases the ability to warm and humidify inspired air. If our hypothesis is correct, it may explain the reason why CPAP is poorly tolerated in patients with sleep apnea; i.e., less ability to warm and humidify air leading to more nasal mucosal irritation.
Interventions
PROCEDUREContinuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water
Sponsors
Fisher and Paykel Healthcare
University of Chicago
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Males and females between 18 and 55 years of age. 2. A clinical history suggestive of normal nose and upper airway, other than during a cold. 3. Willingness of the subject to participate in and complete the study, and the ability to understand the purpose of the trial.
Exclusion criteria
1. Physical sign or symptoms suggestive of renal, hepatic or cardiovascular disease. 2. Women of childbearing potential who are pregnant, trying to become pregnant or nursing a child. 3. Subjects treated with systemic steroids during the previous 30 days. 4. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 15 days. 5. Subjects treated with oral antihistamine/decongestants during the previous seven days. 6. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days. 7. Subjects treated with immunotherapy. 8. Subjects on chronic anti-asthma medications. 9. Subjects with polyps in the nose or a significantly displaced septum. 10. Subjects who have incurred an upper respiratory tract infection within 14 days of the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of water evaporated during the last 5 minutes of exposure to cold, dry air | — |
Countries
United States
Outcome results
None listed